Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Index funds and ETFs each have roles; this note explains when index funds offer a simpler, cost-effective path for many investors.
26,830 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
AI is reshaping business, and a few durable names stand to benefit for years. Here are three artificial intelligence ...
Two very different approaches to growth: Nvidia leads AI hardware and software, while Strategy blends software with B...
With July 16 earnings just days away, Taiwan Semiconductor is shaping up as a high-conviction play thanks to expandin...
A year after XRP surged to $3.65, ripple (xrp) peaked $3.65 remains a milestone. Today, the token is far lower as reg...
Caterpillar has powered through a demanding cycle, but can its momentum persist into 2026? This guide digs into the d...
CrowdStrike’s ARR growth has reaccelerated, but does that make the stock a buy? This guide breaks down ARR health, ma...
Investors have watched Peloton stumble from its pandemic-era peak to today’s volatile trading. This guide digs into w...
When a tech titan speaks, markets listen. This article breaks down NVIDIA's latest signals from the GTC AI conference...
A renewable-powered data-center company, Iren, surged after unveiling a multi-year Nvidia partnership and ambitious A...
When a hedge fund takes position in a logistics stock, it often signals confidence in the sector's growth prospects a...
As Target prepares for its Q1 2026 earnings call, savvy investors want clarity on sales growth, margins, and the path...